[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338136-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338136-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mybl2-drives-prostate-cancer-plasticity-inhibiting-its-transcriptional-target-cdk2-for-rb1-deficient-neuroendocrine-prostate-cancer","MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer","","Phenotypic plasticity is a key mechanism behind therapeutic resistance in prostate cancer, yet its actionable molecular causes remain incompletely addressed. Using a multiomic strategy with genetically engineered mouse models and patient data, MYB proto-oncogene like 2 (MYBL2) emerged as a highly enriched master regulator transcription factor driving plasticity. Genetic Mybl2 inhibition reduced in vivo growth and cell fitness, repressing pluripotency and stemness programs. Since MYBL2 is not directly druggable, MYBL2 signatures implicated CDK2, where CDK2 inhibition decreased tumor growth and increased DNA damage.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mybl2-drives-prostate-cancer-plasticity-inhibiting-its-transcriptional-target-cdk2-for-rb1-deficient-neuroendocrine-prostate-cancer/338136/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mybl2-drives-prostate-cancer-plasticity-inhibiting-its-transcriptional-target-cdk2-for-rb1-deficient-neuroendocrine-prostate-cancer/338136.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does MYBL2 play in prostate cancer phenotypic plasticity?","Question",{"text":63,"@type":64},"MYBL2 is identified as a significantly enriched transcription factor and master regulator driving phenotypic plasticity in prostate cancer. Genetic inhibition of Mybl2 decreases growth and cell fitness while repressing pluripotency/stemness-related gene expression programs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why was CDK2 considered after MYBL2 was found to be non-druggable?",{"text":68,"@type":64},"Because MYBL2 is currently not druggable, the study used a MYBL2 gene signature to nominate downstream therapeutic vulnerabilities. Cyclin-dependent kinase-2 (CDK2) was identified as a potential target.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the effect of inhibiting CDK2 in RB1-deficient neuroendocrine prostate cancer?",{"text":72,"@type":64},"CDK2 inhibition phenocopied genetic loss of Mybl2 and significantly reduced in vivo tumor growth. The treatment was associated with increased enrichment of DNA damage, indicating impaired survival and proliferative capacity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338136,1790143823,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-24-0069](https://doi.org/10.1158/2767-9764.CRC-24-0069)  OPEN ACCESS  \nMYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer  \nBeatriz German1,2,3,4, Sarah A. Alaiwi5, Kun-Lin Ho1,2,3, Jagpreet S. Nanda6, Marcos A. Fonseca7, Deborah L. Burkhart8, Anjali V. Sheahan9, Hannah E. Bergom10, Katherine L. Morel11, Himisha Beltran12, Justin H. Hwang10, Matthew L. Freedman12, Kate Lawrenson7,13, and Leigh Ellis1,2,3,4  \n􀀶  \nABSTRACT  \nPhenotypic plasticity is a recognized mechanism driving therapeutic resistance in patients with prostate cancer. Although underlying molecular causations driving phenotypic plasticity have been identified, therapeutic success is yet to be achieved. To identify putative master regulator transcription factors (MR-TF) driving phenotypic plasticity in prostate cancer, this work utilized a multiomic approach using genetically engineered mouse models of prostate cancer combined with patient data to identify MYB proto-oncogene like 2 (MYBL2) as a significantly enriched transcription factor in prostate cancer exhibiting phenotypic plasticity. Genetic inhibition of Mybl2 using independent murine prostate cancer cell lines representing phenotypic plasticity demonstrated Mybl2 loss significantly decreased in vivo growth as well as cell fitness and repressed gene expression signatures involved in pluripotency and stemness. Because MYBL2 is  \ncurrently not druggable, a MYBL2 gene signature was employed to identify cyclin-dependent kinase-2 (CDK2) as a potential therapeutic target. CDK2 inhibition phenocopied genetic loss of Mybl2 and significantly decreased in vivo tumor growth associated with enrichment of DNA damage. Together, this work demonstrates MYBL2 as an important MR-TF driving phenotypic plasticity in prostate cancer. Furthermore, high MYBL2 activity identifies prostate cancer that would be responsive to CDK2 inhibition.  \nSignificance: Prostate cancers that escape therapy targeting the androgen receptor signaling pathways via phenotypic plasticity are currently untreatable. Our study identifies MYBL2 as a MR-TF in phenotypic plastic prostate cancer and implicates CDK2 inhibition as a novel therapeutic target for this most lethal subtype of prostate cancer.  \nIntroduction  \nSecond-generation androgen deprivation therapies have provided significant life-extending therapies for patients with recurrent or metastatic castrationresistant prostate cancer (mCRPC) . Most recently, a subset of these mCRPC tumors progress after androgen deprivation therapies via phenotypic plasticity that allows the cell to adopt phenotypes that no longer rely on  \n1Department of Surgery, Center for Prostate Disease Research, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland. 2Walter Reed National Military Medical Center, Bethesda, Maryland. 3The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland. 4Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. 5Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut. 6Department of Urology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California. 7Department of Obstetrics and Gynecology and the Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. 8Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 9Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 10Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, Minnesota. 11South  \nandrogen receptor (AR) expression and signaling (CRPC-AI) . Genetic aberrations such as ","cbCaickNZBYCJnhU","https://ap.wps.com/l/cbCaickNZBYCJnhU","pdf",23327170,13,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What role does MYBL2 play in prostate cancer phenotypic plasticity?\",\"answer\":\"MYBL2 is identified as a significantly enriched transcription factor and master regulator driving phenotypic plasticity in prostate cancer. Genetic inhibition of Mybl2 decreases growth and cell fitness while repressing pluripotency/stemness-related gene expression programs.\"},{\"question\":\"Why was CDK2 considered after MYBL2 was found to be non-druggable?\",\"answer\":\"Because MYBL2 is currently not druggable, the study used a MYBL2 gene signature to nominate downstream therapeutic vulnerabilities. Cyclin-dependent kinase-2 (CDK2) was identified as a potential target.\"},{\"question\":\"What is the effect of inhibiting CDK2 in RB1-deficient neuroendocrine prostate cancer?\",\"answer\":\"CDK2 inhibition phenocopied genetic loss of Mybl2 and significantly reduced in vivo tumor growth. The treatment was associated with increased enrichment of DNA damage, indicating impaired survival and proliferative capacity.\"}]","MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer | PDF",1790022126,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1527b1f3fac8f991e40a152c0e2d6d20.webp",983,1263,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/425ec7918033dc9c364884adf2c51588.webp",982,1262,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98d6ce4a19af3f1f0265be4e86cab993.webp",981,1261,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac76c3e212a8e534daad2c36742ab7e8.webp",980,1259]